Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Etripamil in Healthy Chinese Subjects
NCT05511870Phase 1Completed
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in paroxysmal supraventricular tachycardia (PSVT) comparing Etripamil 70mg with Placebo (2 arms). Primary endpoints: Cmax of Etripamil after single dosing and Cmax of MSP-2030 after single dosing. Started Mar 2023; status: completed.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NCT05511870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511870.